NASDAQ · PRLDHealthcarePharmaceuticals

Prelude Therapeutics Incorporated news

$3.96+1.28%

Close Sep 29, 2026 · split-adjusted

Articles · 30 days0English, de-duplicated

Positive0

Neutral0

Negative0

About Prelude Therapeutics Incorporated

Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026

GlobeNewswire Inc.Apr 20, 6:00 AM ET▲ Positive

The company announced promising preclinical data showing complete tumor regressions as monotherapy, improved safety profile compared to competitors, synergy with standard of care treatments, and remains on track for IND filing and clinical trial initiation timelines. These developments represent significant progress toward clinical advancement of their lead candidate.

Also mentions PRLD

Articles that tag PRLD but are mainly about other companies.

None recently.

Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology